Skip to content

CHICAGO EQUITY PARTNERS LLC: XRAY position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of CHICAGO EQUITY PARTNERS LLC on XRAY, newest first. How the timeline and the estimate are built.

CHICAGO EQUITY PARTNERS LLC held 59,450 XRAY shares at 2020-03-31 per its 13F-HR filed 2020-05-06.

the latest 13F is the newest step

  1. period ended2020-03-31
    13F 59,450 shares
    Change vs previous 13F -4,105 shares

    0.23% of the 13F portfolio, value $2,308,000.

    13F-HR 0001221073-20-000092 filed by CHICAGO EQUITY PARTNERS LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2019-12-31
    13F 63,555 shares
    Change vs previous 13F -5,715 shares

    0.21% of the 13F portfolio, value $3,597,000.

    13F-HR 0001085146-20-000514 filed by CHICAGO EQUITY PARTNERS LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2019-09-30
    13F 69,270 shares
    Change vs previous 13F +5,970 shares

    0.18% of the 13F portfolio, value $3,693,000.

    13F-HR 0001085146-19-002673 filed by CHICAGO EQUITY PARTNERS LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2019-06-30
    13F 63,300 shares
    Change vs previous 13F +42,385 shares

    0.16% of the 13F portfolio, value $3,694,000.

    13F-HR 0001085146-19-002053 filed by CHICAGO EQUITY PARTNERS LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2019-03-31
    13F 20,915 shares
    Change vs previous 13F not available

    0.04% of the 13F portfolio, value $1,037,000.

    13F-HR 0001085146-19-001514 filed by CHICAGO EQUITY PARTNERS LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).